Saranac Partners’s Novo Nordisk NVO Stock Holding History

Saranac Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$532K	Buy	+11,090	New	+$476K	0.16%	72

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Saranac Partners's NVO Position: Q2 2026 in Review

Saranac Partners opened a new position in Novo Nordisk (NVO) in Q2 2026: 11,090 shares worth $532K. The stake represents 0.16% of the portfolio and ranks #72 among its holdings.

1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Saranac Partners held 11,090 shares of Novo Nordisk worth $532K as of Q2 2026.
Novo Nordisk was a new Saranac Partners position in Q2 2026.
Novo Nordisk made up 0.16% of Saranac Partners's portfolio in Q2 2026, its #72 holding.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Saranac Partners's 13F filing for Q2 2026, filed 13 Aug 2026.